

2024 Society of Neuro-Oncology  
Annual Conference

# Servier Pharmaceuticals Sponsored Abstracts



# ABSTRACTS

2024 Society of Neuro-Oncology  
Annual Conference

**SERVIER** 

## Date & Time

## Title

## Presentation

**Sat Nov. 23, 2024**

10:45 a.m. - 12:15 p.m.

A phase 1, randomized, perioperative trial of vorasidenib and ivosidenib in IDH1-mutant diffuse glioma: updated results.

**Oral Presentation**

IK Mellinghoff (MSKCC)

**Fri Nov. 22, 2024**

7:30 - 9:30 p.m.

A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH-1 mutant glioma: trial in progress.

**Poster Presentation**

PY Wen (DFCI)

**Fri Nov. 22, 2024**

7:30 - 9:30 p.m.

IDH-mutant glioma patients treated with vorasidenib: ongoing data from the vorasidenib expanded access program.

**Poster Presentation**

TF Cloughesy (UCLA)

**Sat Nov. 23, 2024**

10:45 a.m. - 12:15 p.m.

Real-world evidence of the frequency of post-surgical initial observation in patients with IDH-mutant glioma.

**Oral Presentation**

M Nisnboym Ziv (Duke)

**Sat Nov. 23, 2024**

10:45 a.m. - 12:15 p.m.

A global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): updated efficacy results.

**Oral Presentation**

IK Mellinghoff (MSKCC)

**Fri Nov. 22, 2024**

7:30 - 9:30 p.m.

Understanding the burden of mIDH1/2 diffuse glioma and the complexity of navigating the patient pathway: Insights from patients and caregivers.

**Poster Presentation**

Kathy Oliver  
(International Brain  
Tumor Alliance)

Find more details on the SNO website